Spruce Street Capital LP — 13F Holdings & Portfolio
CIK 2050194 · latest 13F-HR filed 2026-08-13
Spruce Street Capital LP manages $509.7M in 13F-reported U.S. long-equity assets across 30 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are KNSA (11.52%), RLAY (10.95%), LBRX (8.76%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions and exited 3; 16 existing positions rose in reported value and 5 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-13
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 70.2%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 2, 2026.
SUITE 1704
NEW YORK, NY 10017
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| BASSEYN, SIMON Control | MANAGING PARTNER & LIMITED PARTNER since Jan 2024 | 25–50% | Individual |
| COHEN, STEPHEN, LESLIE Control | CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER since Apr 2024 | Less than 5% | Individual |
| ROSEN, ALEX, RYAN Control | MANAGING PARTNER & LIMITED PARTNER since Jan 2024 | 25–50% | Individual |
| SPRUCE STREET CAPITAL GP LLC Control | GENERAL PARTNER since Feb 2024 | Less than 5% | Domestic Entity |
| BASSEYN, SIMON Control Indirect owner via SPRUCE STREET CAPITAL GP LLC | MANAGING MEMBER since Jan 2024 | 50–75% | Individual |
| ROSEN, ALEX, RYAN Control Indirect owner via SPRUCE STREET CAPITAL GP LLC | MANAGING MEMBER since Jan 2024 | 50–75% | Individual |
Ownership & leadership changes · 2 filings with changes since Oct 9, 2024
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedSPRUCE STREET CAPITAL GP LLC · now a control person
- ChangedBASSEYN, SIMON · title MANAGING PARTNER → MANAGING PARTNER & LIMITED PARTNER
- ChangedROSEN, ALEX, RYAN · title MANAGING PARTNER → MANAGING PARTNER & LIMITED PARTNER
- ListedBASSEYN, SIMON · MANAGING PARTNER · 25–50% · control person
- ListedBASSEYN, SIMON · MANAGING MEMBER · 50–75% · indirect via SPRUCE STREET CAPITAL GP LLC · control person
- ListedCOHEN, STEPHEN, LESLIE · CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER · Less than 5% · control person
- ListedROSEN, ALEX, RYAN · MANAGING PARTNER · 25–50% · control person
- ListedROSEN, ALEX, RYAN · MANAGING MEMBER · 50–75% · indirect via SPRUCE STREET CAPITAL GP LLC · control person
- ListedSPRUCE STREET CAPITAL GP LLC · GENERAL PARTNER · Less than 5%
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- RELAY THERAPEUTICS INC$26.1M +88.0%
- KINIKSA PHARMACEUTICALS INTL$22.1M +60.2%
- ALKERMES PLC$17.3M +153.4%
- LB PHARMACEUTICALS INC$11.0M +32.7%
- ALTO NEUROSCIENCE INC$6.6M +22.6%
Top Trims
- SURROZEN INC-$1.4M -10.9%
- LEXEO THERAPEUTICS INC-$1.0M -18.9%
- MINERVA NEUROSCIENCES INC-$786.4K -7.9%
- ALECTOR INC-$294.1K -6.5%
- LEONABIO INC-$226.8K -5.9%
New Positions
- INFLARX NV$12.0M
- RESEARCH ALLIANCE CORP III$5.3M
- ZAI LAB LTD$5.3M
- ACHIEVE LIFE SCIENCE INC$4.8M
- JATT II ACQUISITION CORP$1.8M
Exited Positions
Show all 3 →Spruce Street Capital LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | KINIKSA PHARMACEUTICALS INTL | KNSA | G52694109 | $58.7M | 11.52% | 918,070 | SH |
| 2 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $55.8M | 10.95% | 2,984,125 | SH |
| 3 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $44.7M | 8.76% | 1,376,159 | SH |
| 4 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $44.2M | 8.68% | 6,391,328 | SH |
| 5 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $35.7M | 7.01% | 1,353,047 | SH |
| 6 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $34.6M | 6.79% | 354,816 | SH |
| 7 | ALKERMES PLC | ALKS | G01767105 | $28.5M | 5.59% | 543,876 | SH |
| 8 | SAVARA INC | SVRA | 805111101 | $21.3M | 4.17% | 3,452,576 | SH |
| 9 | VAXCYTE INC | PCVX | 92243G108 | $17.8M | 3.49% | 306,047 | SH |
| 10 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $16.7M | 3.28% | 329,006 | SH |
| 11 | ENANTA PHARMACEUTICALS INC | ENTA | 29251M106 | $15.9M | 3.11% | 1,088,731 | SH |
| 12 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $12.6M | 2.47% | 3,693,931 | SH |
| 13 | INFLARX NV | IFRX | N44821101 | $12.0M | 2.35% | 5,352,198 | SH |
| 14 | SURROZEN INC | SRZN | 86889P208 | $11.2M | 2.20% | 432,040 | SH |
| 15 | ALUMIS INC | ALMS | 022307102 | $11.0M | 2.17% | 392,574 | SH |
| 16 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $9.9M | 1.95% | 4,059,054 | SH |
| 17 | MINERVA NEUROSCIENCES INC | NERV | 603380205 | $9.2M | 1.80% | 1,655,500 | SH |
| 18 | SAB BIOTHERAPEUTICS INC | SABS | 78397T202 | $8.6M | 1.68% | 2,198,502 | SH |
| 19 | AN2 THERAPEUTICS INC | ANTX | 037326105 | $8.0M | 1.58% | 1,661,073 | SH |
| 20 | ERASCA INC | ERAS | 29479A108 | $7.7M | 1.52% | 422,543 | SH |
| 21 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $7.3M | 1.43% | 3,581,603 | SH |
| 22 | RESEARCH ALLIANCE CORP III | RACC | G75226103 | $5.3M | 1.05% | 500,000 | SH |
| 23 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $5.3M | 1.04% | 500,000 | SH |
| 24 | ZAI LAB LTD | ZLAB | 98887Q104 | $5.3M | 1.04% | 279,110 | SH |
| 25 | ACHIEVE LIFE SCIENCE INC | ACHV | 004468500 | $4.8M | 0.94% | 736,637 | SH |
| 26 | LEXEO THERAPEUTICS INC | LXEO | 52886X107 | $4.3M | 0.85% | 928,593 | SH |
| 27 | ALECTOR INC | ALEC | 014442107 | $4.2M | 0.83% | 2,101,068 | SH |
| 28 | LEONABIO INC | LONA | 04746L203 | $3.6M | 0.71% | 393,701 | SH |
| 29 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $3.5M | 0.68% | 231,585 | SH |
| 30 | JATT II ACQUISITION CORP | JATT | G50765109 | $1.8M | 0.36% | 160,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $509.7M | 30 | 0002050194-26-000005 |
| 2026-03-31 | 2026-05-14 | $415.9M | 28 | 0002050194-26-000004 |
| 2025-12-31 | 2026-02-13 | $302.7M | 27 | 0002050194-26-000001 |
SUITE 1704
NEW YORK, NY 10017